Drug Profile
Istiratumab - Merrimack Pharmaceuticals
Alternative Names: MM-141Latest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator Adimab
- Developer Merrimack Pharmaceuticals
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ovarian cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 25 Jun 2018 Discontinued - Phase-II for Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease) in Belgium (Parenteral)
- 25 Jun 2018 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease) in USA (Parenteral)